Survival Disparities of Diffuse Large B-Cell Lymphoma (DLBCL) in a Community-Based Inner-City Cancer Center

Publication date: Available online 9 October 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Andrew Tiu, Vinicius Jorge, Peter Moussa, Djeneba Audrey Djibo, Sorab Gupta, Onder Alpdogan, Claudia Dourado
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research

Related Links:

Publication date: October 2020Source: Clinical Lymphoma Myeloma and Leukemia, Volume 20, Issue 10Author(s): Prajwal Dhakal, Elizabeth Lyden, Kate-Lynn E. Muir, Zaid S. Al-Kadhimi, Lori J. Maness, Krishna Gundabolu, Vijaya Raj Bhatt
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
(University of Pennsylvania School of Medicine) New research has uncovered the previously unknown presence of CD19 -- a B cell molecule targeted by chimeric antigen receptor (CAR) T cell immunotherapy to treat leukemia, lymphoma, and multiple myeloma -- in brain cells that protect the blood brain barrier (BBB). This discovery may potentially be the cause for neurotoxicity in patients undergoing CD19 directed CAR T cell immunotherapy, according to the research team led by Avery Posey, PhD, an assistant professor of Systems Pharmacology and Translational Therapeutics at the University of Pennsylvania.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
The COVID-19 pandemic has proven to have significant morbidity and mortality in high risk patient populations including those with cancer. Chronic lymphocytic leukemia (CLL) is an indolent disease and the majority of patients with CLL are under monitoring. Here we present a case of a CLL patient with severe COVID-19 presenting with marked lymphocytosis within 2-3 days of diagnosis. An 80-years old man with treatment na ïve CLL was admitted to our hospital for COVID-19 pneumonia. He was intubated due to hypoxic respiratory failure and developed multi-system organ failure requiring hemodialysis and vasopressor therapy.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Case Report Source Type: research
esco Albano Immunomodulatory drugs (IMiDs) are analogs of thalidomide. They have immunomodulatory, antiangiogenic and proapoptotic properties and exert a role in regulating the tumor microenvironment. Recently IMiDs have been investigated for their pleiotropic properties and their therapeutic applications in both solid tumors (melanoma, prostate carcinoma and differentiated thyroid cancer) and hematological malignancies. Nowadays, they are applied in de novo and relapsed/refractory multiple myeloma, in myelodysplastic syndrome, in del5q syndrome with specific use of lenalidomide and B-cell lymphoma. Several studies hav...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Abstract Chronic lymphocytic leukaemia (CLL) is a disease of the elderly, most frequently diagnosed among people aged 65-74 years.1 Aging brings about a reduction of the functional reserves of organs and systems, translating into a reduced tolerance to treatment. Although aging and frailty are two concepts that have always gone hand-in-hand, chronological age alone is not a sufficient measure of fitness. Some elderly patients have no comorbidity and are functionally independent; others struggle with comorbidities, polypharmacy, functional dependence, or cognition and mood problems. Patients of the same age can hav...
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Tags: Clin Lymphoma Myeloma Leuk Source Type: research
CONCLUSIONS: There was no convincing evidence of an increased risk in any hematological malignancy when interpreting the results from both series of analyses. PMID: 32818321 [PubMed - as supplied by publisher]
Source: Transfusion - Category: Hematology Authors: Tags: Transfusion Source Type: research
We assessed the quality of life and symptom burden in patients with chronic-phase chronic myeloid leukemia (CML) receiving first- or second-generation tyrosine kinase inhibitors, to demonstrate whether there are differences between tyrosine kinase inhibitor generations. A total of 121 patients with CML with good performance and low comorbidity scores were enrolled in the study. Similar results were observed between the groups in the quality of life and symptom burden scores, which were examined using CML-specific (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Chronic Myeloid Leuke...
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
ssi D Abstract Long non-coding RNAs (lncRNAs) play critical roles in various biological functions and disease processes including cancer. The metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) was initially identified as a lncRNA with elevated expression in primary human non-small cell lung tumors with high propensity to metastasize, and subsequently shown to be highly expressed in numerous other human cancers including breast, ovarian, prostate, cervical, endometrial, gastric, pancreatic, sarcoma, colorectal, bladder, brain, multiple myeloma, and lymphoma. MALAT1 is deeply involved in several physiol...
Source: Free Radical Biology and Medicine - Category: Biology Authors: Tags: Free Radic Biol Med Source Type: research
Multiple myeloma (MM) is a neoplastic proliferation of plasma  cells in the bone marrow, accounting for 1% of all cancers and ∼ 10% of all hematologic malignancies.1 MM diagnosis requires ≥ 10% clonal bone marrow plasma cells or a biopsy-proven plasmacytoma plus evidence of one or more MM-defining events: CRAB features related to the plasma cell disorder (ie, hypercalcemia [C], renal failure [R], anemia [A], or lytic bone lesions [B]), bone marrow clonal plasmacytosis ≥ 60%, serum involved/uninvolved free light chain (FLC) ratio ≥ 100 (provided involved FLC is ≥ 100 mg/L), or> 1 ...
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Case Report Source Type: research
Multiple myeloma (MM) is a neoplastic proliferation of plasma cells in the bone marrow, accounting for 1% of all cancers and ∼10% of all hematological malignancies.1 MM diagnosis requires ≥10% clonal bone marrow plasma cells or a biopsy-proven plasmacytoma plus evidence of one or more MM defining events: CRAB features related to the plasma cell disorder (i.e., hypercalcemia [C], renal failure [R], anemia [A], or lytic bone lesions [B]), bone marrow clonal plasmacytosis ≥60%, serum involved/uninvolved free light chain (FLC) ratio ≥100 (provided involved FLC is ≥100 mg/L), or>1 focal lesion on magnetic res...
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Case Report Source Type: research
More News: Cancer | Cancer & Oncology | Leukemia | Lymphoma | Myeloma